These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24687512)

  • 41. Pharmacological therapy of Helicobacter pylori infection.
    Hoffman JS
    Semin Gastrointest Dis; 1997 Jul; 8(3):156-63. PubMed ID: 9232728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.
    Treiber G; Malfertheiner P; Klotz U
    Expert Opin Pharmacother; 2007 Feb; 8(3):329-50. PubMed ID: 17266468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience.
    Tan B; Yang JC; Young CL; Bishu S; Owyang SY; El-Zaatari M; Zhang M; Grasberger H; Qian JM; Kao JY
    Dig Dis Sci; 2018 Feb; 63(2):437-445. PubMed ID: 29264696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eradication of Helicobacter pylori: recent advances in treatment.
    McLoughlin RM; O'Morain CA; O'Connor HJ
    Fundam Clin Pharmacol; 2005 Aug; 19(4):421-7. PubMed ID: 16011728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effective regimens for the treatment of Helicobacter pylori infection.
    Morgner A; Labenz J; Miehlke S
    Expert Opin Investig Drugs; 2006 Sep; 15(9):995-1016. PubMed ID: 16916269
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates.
    Wang B; Zhao Q; Yin W; Yuan Y; Wang X; Wang YH; Wang H; Ye W; Chen S; Guo HL; Xie Y
    Swiss Med Wkly; 2018; 148():w14630. PubMed ID: 30044468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antimicrobial activities of ethanol and butanol fractions of white rose petal extract.
    Park D; Shin K; Choi Y; Guo H; Cha Y; Kim SH; Han NS; Joo SS; Choi JK; Lee YB; Choi EK; Kim JB; Kim YB
    Regul Toxicol Pharmacol; 2016 Apr; 76():57-62. PubMed ID: 26802535
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
    Srinarong C; Siramolpiwat S; Wongcha-um A; Mahachai V; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(22):9909-13. PubMed ID: 25520127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibiotic treatment strategies for Helicobacter pylori infection.
    Campo SM; Zullo A; Hassan C; Morini S
    Recent Pat Antiinfect Drug Discov; 2007 Jan; 2(1):11-7. PubMed ID: 18221161
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
    Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
    Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial activity of aminoreductone against Helicobacter pylori.
    Trang VT; Takeuchi H; Kudo H; Aoki A; Katsuno S; Shimamura T; Sugiura T; Ukeda H
    J Agric Food Chem; 2009 Dec; 57(23):11343-8. PubMed ID: 19891477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potent antibacterial activity of Y-754, a novel benzimidazole compound with selective action against Helicobacter pylori.
    Iwao E; Yamamoto K; Yokoyama Y; Hirayama F; Haga K
    J Infect Chemother; 2004 Apr; 10(2):90-6. PubMed ID: 15160301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease.
    Tytgat GN
    Aliment Pharmacol Ther; 1995; 9 Suppl 1():39-42. PubMed ID: 7495941
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
    Xiao SD; Liu WZ; Hu PJ; Xia DH; Tytgat GN
    Aliment Pharmacol Ther; 1999 Mar; 13(3):311-5. PubMed ID: 10102963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro antibacterial activity of Phx-3 against Helicobacter pylori.
    Hanawa T; Osaki T; Manzoku T; Fukuda M; Kawakami H; Tomoda A; Kamiya S
    Biol Pharm Bull; 2010; 33(2):188-91. PubMed ID: 20118538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori
    Luo P; Huang Y; Hang X; Tong Q; Zeng L; Jia J; Zhang G; Bi H
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318002
    [No Abstract]   [Full Text] [Related]  

  • 60. Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal.
    Seck A; Mbengue M; Gassama-Sow A; Diouf L; Ka MM; Boye CS
    J Infect Dev Ctries; 2009 Sep; 3(2):137-40. PubMed ID: 19755744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.